| Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the … CD Blanke, C Rankin, GD Demetri, CW Ryan, M Von Mehren, ... Journal of clinical oncology 26 (4), 626-632, 2008 | 1338 | 2008 |
| Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal … MC Heinrich, K Owzar, CL Corless, D Hollis, EC Borden, CDM Fletcher, ... Journal of clinical oncology 26 (33), 5360-5367, 2008 | 756 | 2008 |
| Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial AJ Armstrong, S Halabi, T Eisen, S Broderick, WM Stadler, RJ Jones, ... The Lancet Oncology 17 (3), 378-388, 2016 | 417 | 2016 |
| Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT … TM Beer, CW Ryan, PM Venner, DP Petrylak, GS Chatta, JD Ruether, ... Journal of Clinical Oncology 25 (6), 669-674, 2007 | 377 | 2007 |
| Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial WD Tap, H Gelderblom, E Palmerini, J Desai, S Bauer, JY Blay, T Alcindor, ... The Lancet 394 (10197), 478-487, 2019 | 335 | 2019 |
| Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America WM Stadler, RA Figlin, DF McDermott, JP Dutcher, JJ Knox, WH Miller Jr, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 295 | 2010 |
| Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre … WD Tap, Z Papai, BA Van Tine, S Attia, KN Ganjoo, RL Jones, S Schuetze, ... The lancet oncology 18 (8), 1089-1103, 2017 | 270 | 2017 |
| A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors SP Patel, M Othus, YK Chae, FJ Giles, DE Hansel, PP Singh, A Fontaine, ... Clinical Cancer Research 26 (10), 2290-2296, 2020 | 264 | 2020 |
| A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer JJ Alumkal, R Slottke, J Schwartzman, G Cherala, M Munar, JN Graff, ... Investigational new drugs 33, 480-489, 2015 | 212 | 2015 |
| Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma LE Davis, V Bolejack, CW Ryan, KN Ganjoo, ET Loggers, S Chawla, ... Journal of Clinical Oncology 37 (16), 1424-1431, 2019 | 211 | 2019 |
| Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group CW Ryan, BH Goldman, PN Lara Jr, PC Mack, TM Beer, CM Tangen, ... Journal of clinical oncology 25 (22), 3296-3301, 2007 | 200 | 2007 |
| Characterization of Lrp, and Escherichia coli regulatory protein that mediates a global response to leucine DA Willins, CW Ryan, JV Platko, JM Calvo Journal of Biological Chemistry 266 (17), 10768-10774, 1991 | 198 | 1991 |
| Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era PC Wu, A Langerman, CW Ryan, J Hart, S Swiger, MC Posner Surgery 134 (4), 656-665, 2003 | 182 | 2003 |
| PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma CW Ryan, O Merimsky, M Agulnik, JY Blay, SM Schuetze, BA Van Tine, ... Journal of Clinical Oncology 34 (32), 3898-3905, 2016 | 180 | 2016 |
| Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer TK Choueiri, RW Ross, S Jacobus, U Vaishampayan, EY Yu, DI Quinn, ... Journal of clinical oncology 30 (5), 507-512, 2012 | 175 | 2012 |
| Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study NB Davis, DA Taber, RH Ansari, CW Ryan, C George, EE Vokes, ... Journal of clinical oncology 22 (1), 115-119, 2004 | 161 | 2004 |
| A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial MER O'Brien, D Watkins, C Ryan, K Priest, C Corbishley, A Norton, ... Annals of oncology 17 (2), 270-275, 2006 | 153 | 2006 |
| Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer CW Ryan, D Huo, LM Demers, TM Beer, LV Lacerna, ... The Journal of urology 176 (3), 972-978, 2006 | 149 | 2006 |
| A review of chemotherapy trials for malignant mesothelioma CW Ryan, J Herndon, NJ Vogelzang Chest 113 (1), 66S-73S, 1998 | 149 | 1998 |
| A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel RW Ross, TM Beer, S Jacobus, GJ Bubley, ME Taplin, CW Ryan, J Huang, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 146 | 2008 |
